Karolinska Development AB (Nasdaq Stockholm: KDEV) published its Interim Report for January-September 2025, revealing exciting data readouts from upcoming clinical studies. Significant events in the third quarter included updates from portfolio companies like Organon, Modus Therapeutics, and Umecrine Cognition. Post-period events included milestones from Dilafor, PharmNovo, and SVF Vaccines (July to November 2025).

Financially, Karolinska Development reported a net loss of SEK -66.8 million for the third quarter of 2025, with a total net loss of SEK -154.3 million for the period January-September 2025. The company’s net asset value was SEK 1,085.4 million at the end of September 2025, with investments totaling SEK 28.4 million in the third quarter (July to September 2025). Cash and cash equivalents stood at SEK 44.5 million on September 30, 2025, reflecting a decrease of SEK 26.6 million from the previous year (October 2025).

Karolinska Development AB, a Nordic life sciences investment company, focuses on breakthrough medical innovations in the Nordic region, investing in companies that advance these assets into commercial products. The company has access to world-class medical innovations and aims to build companies around scientists supported by experienced management teams and international investors (July 2025).

Read more at GlobeNewswire: Interim Report – January-September 2025